Publications

Cancers

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

04-12-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

01-12-2019

European journal of cancer (Oxford, England : 1990)

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.

01-12-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Gender medicine and oncology: report and consensus of an ESMO workshop.

01-12-2019

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.

01-11-2019

European journal of cancer (Oxford, England : 1990)

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

01-11-2019

Oncoimmunology

Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.

28-10-2019

The New England journal of medicine

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

17-10-2019

Immuno-oncology technology

The promise of IO and IOTECH.

01-10-2019

European urology

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

01-10-2019

Immuno-oncology technology

Getting visible with exciting IO tech!

01-09-2019

European journal of cancer (Oxford, England : 1990)

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

01-09-2019

ESMO open

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

20-08-2019

ESMO open

Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs.

20-08-2019

The New England journal of medicine

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

15-08-2019

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

01-08-2019

Cancers

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

18-07-2019

Journal for immunotherapy of cancer

Transgenerational transfer of gene-modified T cells.

15-07-2019

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Future oncology (London, England)

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

01-07-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

01-07-2019

ESMO open

How I treat MSI cancers with advanced disease.

25-06-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

01-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Insights into imaging

Cryoablation and immunotherapy: an overview of evidence on its synergy.

20-05-2019

Cancer immunology, immunotherapy : CII

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

01-05-2019

Virchows Archiv : an international journal of pathology

Adoptive cellular therapies: the current landscape.

01-04-2019

Nature medicine

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

01-04-2019

The New England journal of medicine

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

21-03-2019

Cancer immunology, immunotherapy : CII

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

01-03-2019

Oncoimmunology

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

07-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

01-02-2019

JAMA oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

01-02-2019

Cancer immunology, immunotherapy : CII

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

01-02-2019

Cancer immunology research

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

01-01-2019

Journal of biotechnology

Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method.

01-01-2019

Nature medicine

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

01-01-2019

Cancer immunology research

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

01-01-2019

The Lancet. Haematology

Characterisation of rare haematological immune-related toxicities.

01-01-2019

Cell

NKG2A, a New Kid on the Immune Checkpoint Block.

13-12-2018

The New England journal of medicine

Sunitinib Alone or after Nephrectomy in Renal Cancer.

08-11-2018

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

01-11-2018

Journal of immunotherapy (Hagerstown, Md. : 1997)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

10-10-2018

Journal for immunotherapy of cancer

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.

03-10-2018

ESMO open

Report on the status of women occupying leadership roles in oncology.

03-10-2018

ESMO open

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.

03-10-2018

Nature reviews. Clinical oncology

Cytoreductive nephrectomy in metastatic renal cancer - less is more.

01-10-2018